## ESTROGEN RECEPTORS IN DISEASES OF THE IMMUNE SYSTEM

Margaret Warner and Jan-Åke Gustafsson

Abstract Estrogen has distinct functions in the immune system where it acts via ER *a* and HER  $\beta$  respectively. Surprisingly, the defects in the immune system which develop in the absence of either ER *a* or ER  $\beta$  are quite distinct from what develops in the absence of estrogen. We have found by studying mice in which either or both estrogen receptors have been inactivated that the two estrogen receptors play distinct roles in the immune system. Loss of ER  $\beta$  leads to chronic myeloid leukemia and loss of ER *a* leads to autoimmune disease. In mice which cannot synthesize estrogen there is also autoimmune disease resembling Sjögren's Syndrome. We plan to study these mice further with the aim of finding the exact sites of action of the two receptors in the immune system and by using specific ligands for ER *a* or ER  $\beta$  to examine how specific parts of the immune system.

Hirosaki Med. J. 59, Supplement : S77-S81, 2007

Estrogen exerts its effects through two distinct receptors, estrogen receptor alpha (ER *a*) and estrogen receptor beta (ER  $\beta$ )<sup>1,2)</sup>. Both receptors are found in nonhematopoietic cells in bone marrow and in B lymphocyte precursors in mouse. ER  $\beta$  has also been found in human spleen<sup>3-6)</sup>. We have used ER  $a^{-/-}$  and  $\text{ER }\beta^{-/-}$  mice to help to elucidate the role of the two receptors in the immune system. Estrogen is a Janus-like molecule with contradictory effects in autoimmune diseases. Although it appears to offer protection against endstage renal disease, during the development of systemic lupus erythematosus (SLE), estrogen blocks the destruction of immature autoreactive B cells in the bone marrow of mice and promotes autoimmunity<sup>7)</sup>. Furthermore, treatment of lupus-prone mice with estrogen increases the incidence of autoimmune disease<sup>8-10)</sup>, while tamoxifen, an ER  $\alpha$  antagonist, seems to suppress SLE<sup>11)</sup>. With the exception of estrogen treatment of neonatal (NZB X NZW F1) mice<sup>12)</sup>, it is generally widely accepted that estrogen aggravates lupus nephritis. In direct contrast, estrogen can suppress the development of the autoimmune exocrinopathy, Sjögren's Syndrome (SS)<sup>13)</sup> and ovariectomy mimics SS in mice of healthy background<sup>14)</sup>.

The incidence of many autoimmune diseases is higher in women<sup>15)</sup>. For this reason it has been speculated for a long time that estrogen plays important roles in the immune system. Loss of estrogen, in ovariectomized mice, results in splenomegaly<sup>16)</sup> and increased production of colony-forming units-granulocyte-erythroidmacrophage-megakaryocytes (CFU-GEMM), burst-forming units-erythroid (BFU-E) cells<sup>17-19)</sup> and B lymphocytes in mouse bone marrow<sup>20)</sup>. Conversely, pregnancy or administration of exogenous estrogen decreases bone marrow B lymphocyte population in mice $^{21,22}$ . Recently, it was shown that estrogen represses the differentiation of multipotent hematopoietic stem cells into both lymphoid and myeloid cells <sup>23,</sup> <sup>24)</sup>. Thus, estrogen is directly implicated in the proliferation and differentiation of various cell

Department of Biosciences and Nutrition, Novum, Karolinska University Hospital, Huddinge, Karolinska Institutet

lineages in normal hematopoietic tissue.

The incidence of end-stage renal disease increases after menopause<sup>25)</sup>. Before menopause, diabetic women have a lower risk of developing this disease than age matched male diabetics $^{25}$ . These data suggest that estrogen may partially prevent the development or progression of renal diseases. The renal glomerulus has been reported to be a direct target tissue for estrogen<sup>26,27)</sup> and there is evidence that an ER a gene polymorphism may be associated with susceptibility to lupus nephritis in males<sup>28)</sup>. Human and mouse mesangial cells, which are the cells involved in the pathogenesis of endstage renal disease, glomerulosclerosis (GS), express both ER a and ER  $\beta^{24}$ . Renal protective effects of estrogen have been demonstrated both in cultured renal proximal tubular cells<sup>29)</sup> and in whole animals. In (GS)-prone mice, estrogen treatment results in a reduced prosclerotic response<sup>30)</sup> and ovariectomy accelerates its progression<sup>31)</sup>. Therefore, it has been suggested that estrogen replacement would help in preventing the progression of end-stage renal disease.

Germinal centres (GC) are sites of immunoglobulin (Ig) class switch, Ig gene V-region somatic hypermutations and B cell tolerization and are thought to be an important site of immune dysregulation in autoimmune disease<sup>32-34)</sup>. In NZB X NZW F1 mice<sup>35)</sup>, a wellcharacterized model of autoimmunity in mice, GC formation occurs in the absence of antigen challenge<sup>35-37)</sup>. There is evidence that murine lymphocytes<sup>38)</sup> and lymphocytes in GC of human lymph nodes<sup>39)</sup> are ER*a* positive. But expression and function of ER*a* in the GC still remains to be investigated by additional methods.

We have found that ER  $a^{-/-}$  mice develop signs of autoimmunity. This is spontaneous and involves ER a but not HER  $\beta^{40}$ . Our results indicate that (1) ER a may have an indispensible function during the development of B-lymphocytes in splenic germinal centres and in the kidney; (2) defects in kidney and immune organs due to aberrant signalling of ER *a* may play central roles in the development of glomerulonephritis; and (3) ER *a*-selective agonists could have beneficial effects in renal disease.

The most striking phenotype in  $\text{ER}\beta^{-/}$  mice is one due to loss of regulation of the immune system<sup>41)</sup>. There is myelogenous hyperplasia in bone marrow, an increase in the number of granulocytes and B lymphocytes in blood, lymphadenopathy and infiltration of leukocytes (mainly granulocytes and few B lymphocytes) in the liver and lung. The number of B cells in the bone marrow and spleen is significantly higher in  $\text{ER}\beta^{-/-}$  mice than in wild-type littermates. As they age,  $\text{ER}\beta^{-/-}$  mice develop a myeloproliferative disease resembling human chronic myeloid leukemia (CML) with lymphoid blast crisis.

Estrogen has been shown to suppress Sjögren's Syndrome (SS). In mouse models of this disease, ovariectomy (Ovx) for 4 months increases production of B lymphocytes in bone marrow and accelerates destructive autoimmune lesions. In mice made estrogen deficient by inactivation of the aromatase gene, aromatase knock-out (ArKO) mice, there is increase in B lymphopoiesis in bone marrow. We evaluated the immune system of aromatase -/- mice and found that by one year, severe destructive autoimmune lesions developed in the salivary glands in female and male ArKO mice. There was a mild but significant infiltration of B lymphocytes in these glands<sup>42)</sup>.

We plan to identify the exact site of action of ER *a* and ER  $\beta$  in the proliferation and differentiation of lineages of the immune system. For this we will use bone marrow cell cultures to study the effects of selective ER *a* and ER  $\beta$ ligands on the growth and differentiation of bone marrow cells.

We will replace estrogen deficient mice with

selective ER *a* and ER  $\beta$  ligands and examine the proliferation and differentiation of cells in the bone marrow, spleen, thymus and blood. We will use FACS analysis to sort and study changes in cell populations in response to these ligands. We will collect the separated cells and examine them for estrogen receptor expression.

We will use human lymphomas and tonsils to examine the distribution of estrogen receptors in human immune tissues and we will begin our study on the search for mutations in estrogen receptors in patients with leukemia, lymphoma and autoimmune disease.

These studies should lead to improved treatment of patients with diseases of the immune system.

## Acknowledgements

This study was supported by a grant from the Swedish Cancer Fund.

## References

- Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-30.
- 2) Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach K. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalphaknockout mouse. Endocrinology 1997;138:4613-21.
- 3)Smithson G, Medina K, Ponting I, Kincade P.W. Estrogen suppresses stromal celldependent lymphopoiesis in culture. J Immunol 1995;155:3409-19.
- 4) Medina KL, Garret KP, Thompson LF, Rossi MID, Payne KJ, Kincade PW. Identification of very early lymphoid precursors in bone marrow and their regulation by estrogen. Nat Immunol 2001;2:718-24.
- 5)Kouro T, Medina KL, Oritani K, Kincade PW. Characteristics of early murine B-lymphocyte precursors and their direct sensitivity to negative

regulators. Blood 2001;97:2708-15.

- 6) Thurmond TS, Murante FG, Staples JE, Silverstone AE, Korach SK, Gasiewicz TA. Role of estrogen receptor alpha in hematopoietic stem cell development and B lymphocyte maturation in the male mouse. Endocrinology 2000;141:2309-18.
- 7)Bynoe MS, Grimaldi CM, Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc Natl Acad Sci USA 2000;97:2703-08.
- 8)Carlsten H, Tarkowski A, Holmdahl R, Nilsson LA. Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice. Clin Exp Immunol 1990;80:467-73.
- 9)Carlsten H, Nilsson N, Jonsson R, Backman K, Holmdahl R, Tarkowski A. Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL lpr/lpr mice. Cell Immunol 1992;144:190-202.
- 10)Peeva E, Grimaldi C, Spatz L, Diamond BJ. Bromocriptine restores tolerance in estrogentreated mice. J Clin Invest 2000;106:1373-9.
- 11) Wu WM, Lin BF, Su YC, Suen JL, Chiang BL. Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice. Scand J Immunol 2000;52:393-400.
- 12) Yamaguchi K, Inoue Y, Hisano M, Unten S, Shimamura T. Disease progression in the systemic lupus erythematosus model mouse (NZB/NZW F1) is inhibited by single shot estrogen treatment in the neonate. Lupus 2003;12:332-4.
- 13) Ishimaru N, Saegusa K, Yanagi K, Haneji N, Saito I, Hayashi Y. Estrogen deficiency accelerates autoimmune exocrinopathy in murine Sjogren's syndrome through fas-mediated apoptosis. Am J Pathol 1999;155:173-81.
- 14) Ishimaru N, Arakaki R, Watanabe M, Kobayashi M, Miyazaki K, Hayashi Y. Development of autoimmune exocrinopathy resembling Sjogren's syndrome in estrogen-deficient mice of healthy background. Am J Pathol 2003;163:1481-90.
- 15) Whitacre CC. Sex differences in autoimmune disease. Nat immunol 2001;2:777-80.

- 16)Zhang J, Pugh TD, Stebler B, Ershler WB, Keller ET. Orchiectomy increases bone marrow interleukin-6 levels in mice. Calcif Tissue Int 1998;62:219-26.
- 17) Erben RG, Raith S, Eberle J, Stangassinger M. Ovariectomy augments B lymphopoiesis and generation of monocyte-macrophage precursors in rat bone marrow. Am J Physiol 1998;274:E476-E83.
- 18) Jilka RL, Passeri G, Girasole G et al. Estrogen loss upregulates hematopoiesis in the mouse: a mediating role of IL-6. Exp Hematol 1995;23:500-6.
- 19) Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992;257:88-91.
- 20) Masuzawa T, Miyaura C, Onoe Y Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. et al. J. Clin. Invest. 1994;94:1090-7.
- 21) Medina K.L, Smithson G, Kincade P.W. Suppression of B lymphopoiesis during normal pregnancy J. Exp. Med.1993; 178(5):1507-15.
- 22) Smithson G, Medina K, Ponting I, Kincade PW. Estrogen suppresses stromal cell-dependent lymphopoiesis in culture. J Immunol 1995;155: 3409-17.
- 23) Medina KL, Garret KP, Thompson LF, Rossi MID, Payne KJ, Kincade PW. Identification of very early lymphoid precursors in bone marrow and their regulation by estrogen. Nat Immunol 2001;2:718-24.
- 24) Kouro T, Medina K.L, Oritani K, Kincade PW. Characteristics of early murine B-lymphocyte precursors and their direct sensitivity to negative regulators. Blood 2001;97:2708-15.
- 25) U.S. Renal Data System: USRDS 2000. (2000) The National Institutes of Health, http://www.usrds. org, NIDDK,
- 26) Potier M, Elliot SJ, Tack I, et al. Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J Am Soc Nephrol 2001;12:241-51.
- 27) Jelinsky SA, Harris HA, Brown EL, et al. Global transcription profiling of estrogen activity: estrogen receptor alpha regulates gene expression in the kidney. J Endocrinology 2003;44:701-10.

- 28) Liu ZH, Cheng ZH, Gong RJ, Liu H, Liu D, Li LS. Sex differences in estrogen receptor gene polymorphism and its association with lupus nephritis in Chinese. Nephron 2002;90:174-80.
- 29) Han HJ, Park SH, Park HJ et al. Effect of various oestrogens on cell injury and alteration of apical transporters induced by tert-butyl hydroperoxide in renal proximal tubule cells. Clin Exp Pharmacol Physiol 2002;29:60-7.
- 30) Potier M, Karl M, Zheng F, Elliot SJ, Striker GE, Striker LJ. Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. Am J Pathol 2002;160:1877-85.
- 31) Elliot SJ, Karl M, Berho M et al. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am J Pathol 2003;162:1441-48.
- 32) Wen L, Pao W, Wong FS et al. Germinal center formation, immunoglobulin class switching, and autoantibody production driven by "non alpha/ beta" T cells. J Exp Med 1996;183:2271-82.
- 33)Kelsoe G. The germinal center: a crucible for lymphocyte selection. Semin Immunol 1996;8:179-184.
- 34) Thorbecke GJ, Amin AR, Tsiagbe VK. Biology of germinal centers in lymphoid tissue. FASEB J 1994;8:832-40.
- 35) Carteron NL, Schimenti CL, Wofsy D. Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion. J Immunol 1989;142:1470-75.
- 36) Miyamoto A, Nakayama K, Imaki H et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta. Nature 2002;416:865-9.
- 37) Wang JH, Avitahl N, Cariappa A, et al. Aiolos regulates B cell activation and maturation to effector state. Immunity 1998;9:543-53.
- 38)Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond BJ. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 2002;109:1625-33.
- 39) Maia DM, Sciarrotta J, Abendroth K, Blatt J.

S 80

Sex steroid receptors in Hodgkin's disease. Leuk Lymphoma 2002;39:365-71.

- 40) Shim GJ, Levente Kis L, Warner M, Gustafsson JÅ. Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. Proc Natl Acad Sci USA 2004;101:1720-4.
- 41) Shim GJ, Wang L, Andersson S, et al. Disruption of the estrogen receptor beta gene in mice causes

myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. Proc Natl Acad Sci USA 2003;100:6694-9.

42)Shim GJ, Warner M, Kim HJ, et al. Aromatasedeficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome. Proc Natl Acad Sci USA 2004;101:12628-33.